Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.

How Big Is The Congestive Heart Failure (CHF) Market Today And What Is Its Future Size?

The market for congestive heart failure (chf) has experienced significant growth in the past several years. Its value is set to increase from $15.94 billion in 2024 to $16.94 billion in 2025, showcasing a compound annual growth rate (CAGR) of 6.3%. This development over the historical period can be credited to factors like a high number of elderly individuals, heightened instances of cardiovascular diseases, growing awareness about cardiac health, increased spending on healthcare, and a surge in the demand for remote patient monitoring.

The market for congestive heart failure (chf) is anticipated to witness robust expansion in the upcoming years, with its value predicted to reach $21.79 billion in 2029, with a compound annual growth rate (CAGR) of 6.5%. The surge in growth during the forecast period can be traced back to factors such as the escalating adoption of digital health solutions, heightened frequency of hypertension, increasing obesity statistics, enhanced patient results, as well as a greater emphasis on tailored medicine. Noteworthy trends projected for this period comprise progress in diagnostic technology, enhancement in treatments, technological leaps in imaging, innovative therapeutic methodologies, and advancements in health wearable devices.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20730&type=smp

Which Demand Drivers Are Strengthening The Congestive Heart Failure (CHF) Market?

The surge in individuals suffering from cardiovascular conditions is anticipated to fuel the expansion of the congestive heart failure (CHF) market. Cardiovascular pertains to both heart and blood vessels, emphasizing their critical function in blood circulation and in overall health maintenance. Sedentary behaviour, unhealthy food habits, ageing demographics, and urbanization contribute to the increasing number of cardiovascular patients, thereby necessitating enhanced healthcare and treatments. In serving the needs of cardiovascular patients, Congestive heart failure (CHF) offers tailored solutions that not only boost heart function and alleviate symptoms, but also prevent further complications, improving patient care and well-being in the process. For example, the American College of Cardiology, a US-based medical society, reported in January 2023 that cardiovascular disease cases surged to 19.8 million in 2022. Further, Eastern Europe displays the highest rate of mortality with 553 deaths per 100,000. Consequently, the burgeoning number of cardiovascular patients is stimulating the growth of the congestive heart failure (CHF) market.

Which Segment Accounts For The Largest Share In The Congestive Heart Failure (CHF) Market?

The congestive heart failure (chf)market covered in this report is segmented –

1) By Type: Systolic Heart Failure; Diastolic Failure; Left-Sided Heart Failure; Right-Sided Heart Failure

2) By Treatment: Medication; Surgery

3) By Diagnosis: Electrocardiogram; Echocardiogram; Magnetic Resonance Imaging (MRI); Stress Test; Blood Tests; Cardiac Catheterization; Other Diagnosis

4) By Distribution Channel: Hospital Pharmacy; Online Pharmacy; Retail Pharmacy

5) By End-User: Hospitals; Specialty Clinics; Ambulatory Surgical Centers; Homecare Settings

Subsegments:

1) By Systolic Heart Failure: Reduced Ejection Fraction (HFrEF); Mild-to-moderate Reduced Ejection Fraction

2) By Diastolic Heart Failure: Preserved Ejection Fraction (HFpEF); Borderline Ejection Fraction (HFpEF)

3) By Left-Sided Heart Failure: Acute Left-Sided Heart Failure; Chronic Left-Sided Heart Failure

4) By Right-Sided Heart Failure: Acute Right-Sided Heart Failure; Chronic Right-Sided Heart Failure

Which Long-Term Trends Will Play A Crucial Role In The Congestive Heart Failure (CHF) Market?

Leading organizations in the congestive heart failure (CHF) market are centering their efforts on groundbreaking innovations such as single intracoronary infusion therapies. These advancements aim to offer efficient medical solutions that can boost the function of the heart as well as enhance the life quality of patients suffering from CHF. Single intracoronary infusion therapy works by delivering medication directly into the coronary artery, resulting in precise treatment for conditions like CHF. For example, in January of 2024, the Germany-based company Bayer AG, in collaboration with the US-based biotechnology firm Asklepios Biopharmaceutical Inc., kickstarted the GenePHIT Phase II trial for AB-1002. AB-1002 is a groundbreaking investigational gene therapy for CHF. Its innovative approach to treatment targets non-ischemic cardiomyopathy, suggesting a potential revolution in the way CHF is treated through sophisticated genetic solutions. The trial is adaptive, double-blind, placebo-controlled, and is set to involve 90 to 150 attendees who have maintained medical stability for a period of not less than four weeks and possess a left ventricular ejection fraction that falls within the 15% and 35% range.

Which Companies Hold A Competitive Edge In The 1233 Market?

Major companies operating in the congestive heart failure (CHF) market are Pfizer Inc., Johnson & Johnson Inc., Boehringer Ingelheim International GmbH, Merck & Co. Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, Abbott Laboratories, Novartis AG., Medtronic Plc, Eli Lilly and Company, Canon Medical Systems Corporation, Novo Nordisk A/S, Jarvik Heart Inc., Boston Scientific Corporation, Applied Molecular Genetics Inc., Biotronik SE & Co. KG, Exelixis Pharmaceuticals Inc., Otsuka Pharmaceutical Co. Ltd., LivaNova

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/congestive-heart-failure-chf-global-market-report

Which Region Is Forecasted To Lead The Congestive Heart Failure (CHF) Market In The Coming Years?

North America was the largest region in the congestive heart failure (CHF) market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the congestive heart failure (CHF) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=20730&type=smp

Browse Through More Reports Similar to the Global Congestive Heart Failure (CHF) Market 2025, By The Business Research Company

Prosthetic Heart Valve Devices And Equipment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/prosthetic-heart-valve-devices-and-equipment-global-market-report

Heart Attack Diagnostic Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/heart-attack-diagnostic-global-market-report

Implantable Heart Pacemaker Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/implantable-heart-pacemaker-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model